S M L Aversa

Summary

Country: Italy

Publications

  1. doi Post-transplant lymphoproliferative disorders after heart or kidney transplantation at a single centre: presentation and response to treatment
    S M L Aversa
    Division of Medical Oncology, Istituto Oncologico Veneto, IRCCS, Padua, Italy
    Acta Haematol 120:36-46. 2008
  2. ncbi Post-transplant lymphoproliferative disorders in liver transplanted patients: a single-centre experience
    D Marino
    Istituto Oncologico Veneto, Via Gattamelata 64, 35100 Padova, Italy
    Anticancer Res 30:2383-91. 2010
  3. ncbi Overdose of Vinblastine in place of Vinorelbine during IGEV chemotherapy
    S M L Aversa
    Departement of Medical Oncology, Istituto Oncologico Veneto, IOV IRCCS, Padua, Italy
    Immunopharmacol Immunotoxicol 34:879-80. 2012
  4. doi Acute cellular rejection and Epstein-Barr virus-related post-transplant lymphoproliferative disorder in a pediatric lung transplant with low viral load
    F Calabrese
    Department of Diagnostic Medical Sciences and Special Therapies, University of Padua, Padua, Italy
    Transpl Infect Dis 12:342-6. 2010
  5. ncbi Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin's lymphomas
    S Monfardini
    Division of Medical Oncology, Azienda Ospedale Universita, Padova
    Ann Oncol 16:1352-8. 2005
  6. doi Comment on: 'Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome'
    D Errante
    Ann Oncol 19:1359-60. 2008

Detail Information

Publications6

  1. doi Post-transplant lymphoproliferative disorders after heart or kidney transplantation at a single centre: presentation and response to treatment
    S M L Aversa
    Division of Medical Oncology, Istituto Oncologico Veneto, IRCCS, Padua, Italy
    Acta Haematol 120:36-46. 2008
    ..Moreover, 4 second neoplasms were observed in the chemotherapeutic group. In this study, we demonstrated that most PTLD need other treatment than RI and a weekly regimen is manageable and has a favourable impact on long-term survival...
  2. ncbi Post-transplant lymphoproliferative disorders in liver transplanted patients: a single-centre experience
    D Marino
    Istituto Oncologico Veneto, Via Gattamelata 64, 35100 Padova, Italy
    Anticancer Res 30:2383-91. 2010
    ..No treatment-related mortality was observed and no patient developed graft rejection during chemotherapy. At a median follow-up period of 25 months, 6 of the 10 patients were alive and without evidence of disease...
  3. ncbi Overdose of Vinblastine in place of Vinorelbine during IGEV chemotherapy
    S M L Aversa
    Departement of Medical Oncology, Istituto Oncologico Veneto, IOV IRCCS, Padua, Italy
    Immunopharmacol Immunotoxicol 34:879-80. 2012
    ..We report herein a case of Vinblastine (VBL) accidental overdose, the cause of mistake, the toxic effect and the salvage therapy adopted in a young lady suffering of Hodgkin relapse during IGEV chemotherapy...
  4. doi Acute cellular rejection and Epstein-Barr virus-related post-transplant lymphoproliferative disorder in a pediatric lung transplant with low viral load
    F Calabrese
    Department of Diagnostic Medical Sciences and Special Therapies, University of Padua, Padua, Italy
    Transpl Infect Dis 12:342-6. 2010
    ..EBV PCR in the peripheral blood is a useful screening tool in transplant recipients; however, rare cases with PTLD may not have detectable levels of EBV DNA. This aspect should be taken into consideration to avoid false negatives...
  5. ncbi Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin's lymphomas
    S Monfardini
    Division of Medical Oncology, Azienda Ospedale Universita, Padova
    Ann Oncol 16:1352-8. 2005
    ..The aim of this study was to evaluate the efficacy and tolerability of vinorelbine and prednisone in frail elderly patients with NHL...
  6. doi Comment on: 'Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome'
    D Errante
    Ann Oncol 19:1359-60. 2008